In recent years, olaparib has been approved for patients with breast cancer possessing mutated BRCA1/2 gene, male patients with metastatic castration-resistant prostate cancer, and patients with metastatic pancreatic cancer in Japan (29, 30). This evidence concerns the gene BRCA1 and breast carcinoma.